1.Yau, J. W. et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35, 556–564 (2012).Article
Google Scholar
2.Daruich, A. et al. Mechanisms of macular edema: Beyond the surface. Prog. Retin. Eye Res. 63, 20–68 (2018).Article
Google Scholar
3.Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 103, 1796–1806 (1985).4.Wells, J. A. et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 123, 1351–1359 (2016).Article
Google Scholar
5.Arevalo, J. F. et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema: The Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology 116, 1488–1497, 1497 e1481 (2009).6.Gillies, M. C. et al. Intravitreal triamcinolone for refractory diabetic macular edema: Two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113, 1533–1538 (2006).Article
Google Scholar
7.Boyer, D. S. et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121, 1904–1914 (2014).Article
Google Scholar
8.Entezari, M. et al. Posterior sub-tenon triamcinolone for refractory diabetic macular edema: A randomized clinical trial. Eur. J. Ophthalmol. 15, 746–750 (2005).CAS
Article
Google Scholar
9.Diabetic Retinopathy Clinical Research, N. et al. Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: A pilot study. Ophthalmology 114, 1190–1196 (2007).10.Hartley, K. L., Smiddy, W. E., Flynn, H. W. Jr. & Murray, T. G. Pars plana vitrectomy with internal limiting membrane peeling for diabetic macular edema. Retina 28, 410–419 (2008).Article
Google Scholar
11.Kumagai, K. et al. Long-term follow-up of vitrectomy for diffuse nontractional diabetic macular edema. Retina 29, 464–472 (2009).Article
Google Scholar
12.Rosenblatt, B. J., Shah, G. K., Sharma, S. & Bakal, J. Pars plana vitrectomy with internal limiting membranectomy for refractory diabetic macular edema without a taut posterior hyaloid. Graefes Arch. Clin. Exp. Ophthalmol. 243, 20–25 (2005).Article
Google Scholar
13.Lee, G. H., Ahn, J. K. & Park, Y. G. Intravitreal triamcinolone reduces the morphologic changes of ciliary body after pars plana vitrectomy for retinal vascular diseases. Am. J. Ophthalmol. 145, 1037–1044 (2008).CAS
Article
Google Scholar
14.Chin, H. S., Park, T. S., Moon, Y. S. & Oh, J. H. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina 25, 556–560 (2005).Article
Google Scholar
15.Chang-Lin, J. E. et al. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest. Ophthalmol. Vis. Sci. 52, 4605–4609 (2011).CAS
Article
Google Scholar
16.Medeiros, M. D. et al. Dexamethasone intravitreal implant in vitrectomized versus nonvitrectomized eyes for treatment of patients with persistent diabetic macular edema. J. Ocul. Pharmacol. Ther. 30, 709–716 (2014).CAS
Article
Google Scholar
17.Iglicki, M. et al. Dexamethasone implant for diabetic macular edema in naive compared with refractory eyes: The international retina group real-life 24-month multicenter study. The IRGREL-DEX Study. Retina 39, 44–51 (2019).CAS
Article
Google Scholar
18.Mello Filho, P. et al. Effectiveness and safety of intravitreal dexamethasone implant (ozurdex) in patients with diabetic macular edema: A real-world experience. Ophthalmologica 241, 9–16 (2019).CAS
Article
Google Scholar
19.Iglicki, M., Zur, D., Busch, C., Okada, M. & Loewenstein, A. Progression of diabetic retinopathy severity after treatment with dexamethasone implant: A 24-month cohort study the “DR-Pro-DEX Study”. Acta Diabetol. 55, 541–547 (2018).CAS
Article
Google Scholar
20.Zur, D. et al. Disorganization of retinal inner layers as a biomarker in patients with diabetic macular oedema treated with dexamethasone implant. Acta Ophthalmol. 98, e217–e223 (2020).CAS
Article
Google Scholar
21.Iglicki, M. et al. TRActional DIabetic reTInal detachment surgery with co-adjuvant intravitreal dexamethasONe implant: the TRADITION STUDY. Acta Diabetol. 56, 1141–1147 (2019).CAS
Article
Google Scholar
22.Lee, D. H., Kim, Y. J. & Yoon, Y. H. Minimally invasive microincision vitrectomy surgery with an intraoperative dexamethasone implant for refractory diabetic macular edema. Ophthalmologica 235, 150–156 (2016).CAS
Article
Google Scholar
23.Kim, K. T. et al. Vitrectomy combined with intraoperative dexamethasone implant for the management of refractory diabetic macular edema. Korean J. Ophthalmol. 33, 249–258 (2019).CAS
Article
Google Scholar
24.Jung, Y. H. & Lee, Y. Efficacy of vitrectomy combined with an intraoperative dexamethasone implant in refractory diabetic macular edema. Acta Diabetol. 56, 691–696 (2019).CAS
Article
Google Scholar
25.Iglicki, M. et al. Biomarkers and predictors for functional and anatomic outcomes for small gauge pars plana vitrectomy and peeling of the internal limiting membrane in naive diabetic macular edema: The VITAL study. PLoS ONE 13, e0200365 (2018).Article
Google Scholar
26.Diabetic Retinopathy Clinical Research Network Writing, C. et al. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology 117, 1087–1093 e1083 (2010).27.Choi, M. Y., Jee, D. & Kwon, J. W. Characteristics of diabetic macular edema patients refractory to anti-VEGF treatments and a dexamethasone implant. PLoS ONE 14, e0222364 (2019).CAS
Article
Google Scholar
28.Flaxel, C. J. et al. Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: Diabetic retinopathy clinical research network. Retina 30, 1488–1495 (2010).Article
Google Scholar
29.Kim, Y. T., Kang, S. W., Kim, S. J., Kim, S. M. & Chung, S. E. Combination of vitrectomy, IVTA, and laser photocoagulation for diabetic macular edema unresponsive to prior treatments; 3-year results. Graefes Arch. Clin. Exp. Ophthalmol. 250, 679–684 (2012).Article
Google Scholar
30.Kim, J., Kang, S. W., Shin, D. H., Kim, S. J. & Cho, G. E. Macular ischemia and outcome of vitrectomy for diabetic macular edema. Jpn. J. Ophthalmol. 59, 295–304 (2015).Article
Google Scholar
31.Yanyali, A., Horozoglu, F., Celik, E. & Nohutcu, A. F. Long-term outcomes of pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Retina 27, 557–566 (2007).Article
Google Scholar
32.Hu, X. Y., Liu, H., Wang, L. N., Ding, Y. Z. & Luan, J. Efficacy and safety of vitrectomy with internal limiting membrane peeling for diabetic macular edema: a Meta-analysis. Int. J. Ophthalmol. 11, 1848–1855 (2018).PubMed
PubMed Central
Google Scholar
33.Stefansson, E. The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol. Scand. 79, 435–440 (2001).CAS
Article
Google Scholar
34.Otani, T. & Kishi, S. A controlled study of vitrectomy for diabetic macular edema. Am. J. Ophthalmol. 134, 214–219 (2002).Article
Google Scholar
35.Antonetti, D. A., Wolpert, E. B., DeMaio, L., Harhaj, N. S. & Scaduto, R. C. Jr. Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J. Neurochem. 80, 667–677 (2002).CAS
Article
Google Scholar
36.Zur, D., Iglicki, M. & Loewenstein, A. The role of steroids in the management of diabetic macular edema. Ophthalmic Res. 62, 231–236 (2019).CAS
Article
Google Scholar
37.Pang, J. P., Son, G., Yoon, Y. H., Kim, J. G. & Lee, J. Y. Combined vitrectomy with intravitreal dexamethasone implant for refractory macular edema secondary to diabetic retinopathy, retinal vein occlusion, and noninfectious posterior uveitis. Retina 40, 56–65 (2020).Article
Google Scholar
38.Chang-Lin, J. E. et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest. Ophthalmol. Vis. Sci. 52, 80–86 (2011).CAS
Article
Google Scholar
39.Avery, R. L. & Gordon, G. M. Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis. JAMA Ophthalmol. 134, 21–29 (2016).Article
Google Scholar
40.Thakur, A., Kadam, R. & Kompella, U. B. Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. Arch Ophthalmol. 129, 914–920 (2011).Article
Google Scholar
41.Yang, Y., Bailey, C., Loewenstein, A. & Massin, P. Intravitreal corticosteroids in diabetic macular edema: pharmacokinetic considerations. Retina 35, 2440–2449 (2015).CAS
Article
Google Scholar